A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective comparative study to determine if an Iodine Gel (Iodosorb◊) is better than standard dressing (Solosite◊ gel) in disruption of biofilm (small microorganism bacteria similar to plaque on teeth) on the wound bed diabetic foot ulcers.

◊ Trademark of Smith \& Nephew

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

NCT03020446

Venous Wound Ulcers

TERMINATED NA

Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

NCT03461783

Wound Infection

COMPLETED NA

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426

Diabetic Foot Ulcer Foot

COMPLETED NA

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy

NCT07086443

Diabetic Foot Ulcer DFU Diabetic Foot Ulcer (DFU) +4 more

RECRUITING PHASE4

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

NCT07089602

Diabetic Foot DFU Diabetic Foot Ulcer +6 more

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IODOSORB gel is a cadexomer iodine product indicated for use in wet ulcers and wounds. As the use of IODOSORB has an anti-microbial effect and removes exudate continuously from the wound, a reduction in pain, odour, oedema, exudate, pus and debris, and microbial load including biofilm can be achieved, hence providing an environment conducive to the normal healing process. While evidence exists to support the use of IODOSORB in diabetic foot ulcers (DFUs) for the reduction of planktonic bacteria, little evidence exits for the effect of any topical therapy on non-planktonic or biofilm bacteria in-vivo. The aim of this study is to explore the effects of IODOSORB on biofilm in the wound, wound healing, and associated factors, such as odour, pain, and reduction of slough.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Solosite gel

Hydrogel with preservatives, used to create a moist wound environment.

Group Type PLACEBO_COMPARATOR

Solosite gel

Intervention Type DEVICE

Hydrogel

Iodosorb

Cadexomer iodine gel

Group Type ACTIVE_COMPARATOR

Iodosorb

Intervention Type DEVICE

Cadexomer iodine gel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iodosorb

Cadexomer iodine gel

Intervention Type DEVICE

Solosite gel

Hydrogel

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient is able to understand the study and is willing to consent to the study.
2. The patient consents to the ongoing use of their de-identified photos by the Sponsor for purposes outside of this study.
3. The patient must be at least 18 years of age.
4. Males and females - provided they are not pregnant or lactating and if of reproductive age are using contraception.
5. The patient has presented with a DFU which, according to the clinical judgement of the Investigator, has a suspected biofilm
6. The patient has a DFU of Grade 1 or 2 according to the Meggit-Wagner scale. Grade 1 - Superficial ulcers limited to the dermis Grade 2 - Ulcers are transdermal with exposed bone or tendon, and without osteomyelitis or abscess formation
7. The patient's ulcer is suitable to be dressed with IODOSORB or SOLOSITE.
8. The patient has an ABPI \>0.49; or toe pressure \>50mmHg.

Exclusion Criteria

1. Patients with a known history of poor compliance with medical treatment.
2. Patients who have participated in this study previously and who healed or were withdrawn.
3. Patients who are participating in any other clinical study.
4. Patients that have received continuous treatment with Iodosorb (on any wound) in the past 8 weeks (Iodosorb must not be continuously used for more 3 months) or whose reference ulcer has been treated with Iodosorb in the past 2 weeks.
5. Patients with a history of any thyroid disorders, e.g. Hashimoto's thyroiditis, Graves disease or non-toxic nodular goitre.
6. Patients undergoing treatment with mercurial antiseptics, taurolidine or lithium.
7. Patients with a known sensitivity to iodine or any of the other ingredients in IODOSORB, SOLOSITE or ALLEVYN Non-adhesive
8. Patients with severe renal impairment
9. Patients with an ulcer less than 3cm diameter.
10. Patients with an ulcer that is not exuding.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No